{"id":37972,"date":"2026-03-04T09:00:00","date_gmt":"2026-03-04T08:00:00","guid":{"rendered":"https:\/\/ggba.swiss\/?p=37972"},"modified":"2026-03-04T09:08:47","modified_gmt":"2026-03-04T08:08:47","slug":"why-life-sciences-companies-choose-switzerland-to-scale-internationally","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/","title":{"rendered":"Why Life Sciences Companies Choose Switzerland to Scale Internationally"},"content":{"rendered":"\n<p>In California, GGBa met with senior executives from biotechnology accelerators, medtech companies, and financial institutions to discuss international scaling strategies and Europe\u2019s evolving innovation landscape.<\/p>\n\n\n\n<p>Across conversations, one theme emerged consistently: companies seeking to expand beyond the United States are not simply looking for geographic presence. They are looking for ecosystems that reduce risk, accelerate execution, and provide long-term stability. In that context, Switzerland is frequently identified as a pragmatic entry point into Europe.<\/p>\n\n\n\n<figure class=\"wp-block-embed aligncenter is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"Why Life Sciences Companies Choose Switzerland to Scale Internationally\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/2ZSfzc1QvdM?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\">Scaling life sciences: beyond science alone<\/h4>\n\n\n\n<p>For biotechnology and medtech companies, scaling is rarely constrained by scientific innovation alone. It is shaped by access to capital, talent availability, regulatory clarity, clinical validation pathways, and long-term business predictability.<\/p>\n\n\n\n<p>Executives emphasized that expansion into Europe remains structurally complex. Unlike the U.S. market, Europe requires multiple market entries, differentiated reimbursement systems, and varied regulatory environments. In this fragmented landscape, choosing the right base becomes critical.<\/p>\n\n\n\n<p>Companies evaluating European expansion therefore prioritize three core elements:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Access to specialized talent<\/li>\n\n\n\n<li>Access to growth-stage capital<\/li>\n\n\n\n<li>Access to infrastructure capable of translating research into clinical and commercial outcomes<\/li>\n<\/ul>\n\n\n\n<p>Switzerland\u2019s ecosystem aligns with these criteria in several ways.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Bridging the \u201cValley of Death\u201d in early-stage innovation<\/h4>\n\n\n\n<p>One recurring theme in discussions was the challenge of funding early-stage life sciences ventures. While seed capital is often available, the critical growth tranche between initial validation and institutional financing remains difficult to secure.<\/p>\n\n\n\n<p>Switzerland\u2019s public innovation funding mechanisms were cited as an important differentiator. Government-backed programs such as Innosuisse provide substantial early-stage support, helping companies bridge the gap between proof-of-concept and clinical development. Compared to smaller early-stage grant structures elsewhere, this level of backing can meaningfully reduce technical and financial risk at the most vulnerable stage of company development.<\/p>\n\n\n\n<p>For international companies, this signals more than funding availability. It reflects a structural willingness to support innovation before commercial success is fully evident, a factor that strengthens the broader ecosystem.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Talent density and scientific concentration<\/h4>\n\n\n\n<p>Access to talent remains a decisive factor in location strategy.<\/p>\n\n\n\n<p>Switzerland\u2019s concentration of life sciences expertise, particularly across Basel, Zurich and Western Switzerland\u2019s \u201cHealth Valley\u201d, creates a dense network of researchers, clinicians, and industry professionals. Universities and research institutions consistently produce high-skilled graduates in advanced modalities such as gene and cell therapy, digital health, and precision medicine.<\/p>\n\n\n\n<p>Executives noted that while Switzerland may not always be the lowest-cost location in Europe, the concentration of expertise and experience reduces execution risk. For companies operating in highly regulated and technically complex environments, quality frequently outweighs cost considerations.<\/p>\n\n\n\n<p>In addition, Switzerland\u2019s international workforce and openness to global talent mirror characteristics often associated with leading U.S. innovation hubs, providing cultural and operational familiarity for American firms.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Clinical credibility and adoption pathways<\/h4>\n\n\n\n<p>For medtech and clinically oriented companies, hospital partnerships and physician engagement are central to European market entry.<\/p>\n\n\n\n<p>Switzerland\u2019s clinical institutions were repeatedly described as advanced, reputationally strong, and open to piloting innovation. Executives pointed to the ability to work with leading hospitals in Bern, Basel, and Zurich as a way to establish validation that carries credibility beyond national borders.<\/p>\n\n\n\n<p>Switzerland\u2019s regulatory organization, CE-marking alignment, and reimbursement clarity also contribute to smoother product integration. The ability to incorporate new technologies into existing clinical workflows without structural disruption was cited as particularly valuable.<\/p>\n\n\n\n<p>In practical terms, Switzerland can function both as a launch environment and as a reference market. Adoption within respected Swiss institutions can support broader European rollout strategies.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Stability as a competitive advantage<\/h4>\n\n\n\n<p>In an industry defined by long development cycles, predictability matters.<\/p>\n\n\n\n<p>Executives highlighted Switzerland\u2019s political and regulatory stability as a strategic asset. Tax frameworks and policy environments are perceived as consistent over time, enabling companies to plan reinvestment and growth with greater confidence.<\/p>\n\n\n\n<p>At both macro and micro levels, stability reduces uncertainty. Companies can negotiate long-term frameworks and operate within a predictable decision-making environment, conditions that are particularly relevant when scaling capital-intensive life sciences operations.<\/p>\n\n\n\n<p>This business-friendly orientation, combined with structural reliability, differentiates Switzerland within a European context often characterized by policy shifts and fragmentation.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Switzerland as a gateway, not just a market<\/h4>\n\n\n\n<p>Beyond its domestic advantages, Switzerland is frequently viewed as a gateway.<\/p>\n\n\n\n<p>Although not a member of the European Union, Switzerland offers access to European markets while maintaining a regulatory and operational environment that is efficient and internationally oriented. This relationship was further reinforced in March 2026, when Switzerland and the EU signed a comprehensive bilateral agreement package strengthening cooperation in health, research programs, and market-related areas, providing greater legal clarity and deeper integration with European frameworks relevant to innovative sectors. For U.S. companies, establishing operations in Switzerland can facilitate broader European engagement while benefiting from a concentrated ecosystem.<\/p>\n\n\n\n<p>Executives also noted cultural alignment between Switzerland and leading U.S. innovation hubs. Entrepreneurial mindset, efficiency in business formation, and openness to international collaboration create operational familiarity.<\/p>\n\n\n\n<p>In this sense, Switzerland is not merely a destination market but a platform for expansion.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Ecosystem thinking over isolated incentives<\/h4>\n\n\n\n<p>A notable takeaway from the discussions was that companies do not evaluate single incentives in isolation. They evaluate ecosystems.<\/p>\n\n\n\n<p>Capital without talent is insufficient. Talent without clinical validation pathways is limiting. Stability without growth potential does not attract expansion.<\/p>\n\n\n\n<p>Switzerland\u2019s strength lies in the combination:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Government-supported early innovation<\/li>\n\n\n\n<li>Concentrated talent in health sciences<\/li>\n\n\n\n<li>Advanced clinical institutions<\/li>\n\n\n\n<li>Stable regulatory and fiscal frameworks<\/li>\n\n\n\n<li>International orientation<\/li>\n<\/ul>\n\n\n\n<p>Together, these elements create an environment where companies can move from research to validation to commercialization with reduced friction.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">The role of ecosystem connectors<\/h4>\n\n\n\n<p>International expansion is rarely executed without local guidance.<\/p>\n\n\n\n<p>During its meetings in California, GGBa emphasized its role in facilitating connections between U.S. companies and relevant Swiss stakeholders. This includes introducing companies to cantonal authorities, research institutions, and industrial partners aligned with their strategic needs.<\/p>\n\n\n\n<p>Rather than positioning Switzerland through marketing claims, the discussions focused on practical pathways: where to locate operations, how to navigate funding programs, how to identify hospital partners, and how to structure long-term growth.<\/p>\n\n\n\n<p>For companies considering European expansion, such ecosystem-level facilitation can accelerate decision-making and reduce entry barriers.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">A strategic European base<\/h4>\n\n\n\n<p>The conversations in California did not suggest that Switzerland is the only option for life sciences expansion. Rather, they highlighted why it is frequently considered one of the most efficient and strategically coherent ones.<\/p>\n\n\n\n<p>In a global life sciences environment characterized by rising competition, technological acceleration, and regulatory complexity, companies increasingly prioritize ecosystems that combine funding continuity, talent density, clinical credibility, and operational stability.<\/p>\n\n\n\n<p>Switzerland\u2019s ability to integrate these factors positions it as a strong candidate for companies seeking to scale internationally.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>As life sciences companies navigate increasingly complex global markets, the decision of where to establish or expand international operations has become a strategic one.<\/p>\n","protected":false},"author":6,"featured_media":37973,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[1199],"tags":[943,952,912,930,949,894,918,929,963,926,883,921,901],"class_list":["post-37972","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-why-switzerland","tag-advanced-manufacturing","tag-bioinformatics","tag-biotech","tag-digital-health","tag-education-en","tag-financing","tag-investment","tag-manufacturing","tag-medical-devices","tag-medtech","tag-oncology","tag-quality-of-life","tag-technology-park"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Why Life Sciences Companies Choose Switzerland to Scale Internationally<\/title>\n<meta name=\"description\" content=\"As life sciences companies navigate global markets, the decision of where to establish international operations has become a strategic one.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Why Life Sciences Companies Choose Switzerland to Scale Internationally\" \/>\n<meta property=\"og:description\" content=\"As life sciences companies navigate global markets, the decision of where to establish international operations has become a strategic one.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-04T08:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-04T08:08:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/03\/Life-Sciences-Scale-Globally-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Why Life Sciences Companies Choose Switzerland to Scale Internationally\",\"datePublished\":\"2026-03-04T08:00:00+00:00\",\"dateModified\":\"2026-03-04T08:08:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/\"},\"wordCount\":1110,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/03\/Life-Sciences-Scale-Globally-1180x811-1.png\",\"keywords\":[\"Advanced Manufacturing\",\"Bioinformatics\",\"Biotech\",\"Digital Health\",\"Education\",\"Financing\",\"Investment\",\"Manufacturing\",\"Medical Devices\",\"Medtech\",\"Oncology\",\"Quality of Life\",\"Technology Park\"],\"articleSection\":[\"Why Switzerland\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/\",\"url\":\"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/\",\"name\":\"Why Life Sciences Companies Choose Switzerland to Scale Internationally\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/03\/Life-Sciences-Scale-Globally-1180x811-1.png\",\"datePublished\":\"2026-03-04T08:00:00+00:00\",\"dateModified\":\"2026-03-04T08:08:47+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"As life sciences companies navigate global markets, the decision of where to establish international operations has become a strategic one.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/03\/Life-Sciences-Scale-Globally-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/03\/Life-Sciences-Scale-Globally-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"As international life sciences competition intensifies, ecosystem strength, not individual incentives, may ultimately determine where innovation turns into lasting impact.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Why Life Sciences Companies Choose Switzerland to Scale Internationally\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Why Life Sciences Companies Choose Switzerland to Scale Internationally","description":"As life sciences companies navigate global markets, the decision of where to establish international operations has become a strategic one.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/","og_locale":"en_US","og_type":"article","og_title":"Why Life Sciences Companies Choose Switzerland to Scale Internationally","og_description":"As life sciences companies navigate global markets, the decision of where to establish international operations has become a strategic one.","og_url":"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-03-04T08:00:00+00:00","article_modified_time":"2026-03-04T08:08:47+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/03\/Life-Sciences-Scale-Globally-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Why Life Sciences Companies Choose Switzerland to Scale Internationally","datePublished":"2026-03-04T08:00:00+00:00","dateModified":"2026-03-04T08:08:47+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/"},"wordCount":1110,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/03\/Life-Sciences-Scale-Globally-1180x811-1.png","keywords":["Advanced Manufacturing","Bioinformatics","Biotech","Digital Health","Education","Financing","Investment","Manufacturing","Medical Devices","Medtech","Oncology","Quality of Life","Technology Park"],"articleSection":["Why Switzerland"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/","url":"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/","name":"Why Life Sciences Companies Choose Switzerland to Scale Internationally","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/03\/Life-Sciences-Scale-Globally-1180x811-1.png","datePublished":"2026-03-04T08:00:00+00:00","dateModified":"2026-03-04T08:08:47+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"As life sciences companies navigate global markets, the decision of where to establish international operations has become a strategic one.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/03\/Life-Sciences-Scale-Globally-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/03\/Life-Sciences-Scale-Globally-1180x811-1.png","width":1180,"height":811,"caption":"As international life sciences competition intensifies, ecosystem strength, not individual incentives, may ultimately determine where innovation turns into lasting impact."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/why-life-sciences-companies-choose-switzerland-to-scale-internationally\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Why Life Sciences Companies Choose Switzerland to Scale Internationally"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/37972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=37972"}],"version-history":[{"count":3,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/37972\/revisions"}],"predecessor-version":[{"id":37993,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/37972\/revisions\/37993"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/37973"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=37972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=37972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=37972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}